2017-09-05T08:29:47-05:00 2016-12-31 521853933 JONES MARESCA & MCQUADE PA 10500 LITTLE PATUXENT PARKWAY SUITE 770 COLUMBIA MD 21044 990 2016-01-01 522320756 ACCELERATE BRAIN CANCER CURE INC ACCE 2024193140 1717 RHODE ISLAND AVENUE NW NO 700 WASHINGTON DC 20036 MAX WALLACE PRESIDENT AND CEO 2024193140 2017-08-16 1 DAVID JONES P01361002 4108840220 64.88.174.3 2017-08-16 11:40:34 ED P 6B3294020F42B9E559A00BBAECB87153F921F36C F2063AAA4B9B21FCE712797224336CC039E4879B 2016 2021-01-29 14:40:06Z MAX WALLACE 1717 RHODE ISLAND AVENUE NW NO 700 WASHINGTON DC 20036 2586402 0 X WWW.ABC2.ORG X 2001 DC ACCELERATE BRAIN CANCER CURE HAS A SINGLE FOCUS-TO HASTEN THE DISCOVERY OF A CURE FOR BRAIN CANCER. 9 9 7 300 0 0 2377196 1961022 0 0 -9813 12328 0 0 2367383 1973350 1401606 911118 0 0 706124 889986 0 0 613315 495461 435062 2603191 2236166 -235808 -262816 3538389 3356332 434881 515640 3103508 2840692 THE PRIMARY OBJECTIVE OF ACCELERATE BRAIN CANCER CURE, INC. IS TO ACCELERATE PROGRESS IN WHAT HAS BEEN AN UNDERSERVED FIELD OF RESEARCH; THE ORGANIZATION AIMS TO RAISE AWARENESS ABOUT BRAIN CANCER AND HELP MOBILIZE CRITICAL SCIENTIFIC RESEARCH THROUGH RESEARCH GRANTS. 0 0 1265113 911118 ACCELERATE BRAIN CANCER CURE, INC. (ABC2) BELIEVES A FOCUSED AND AGGRESSIVE ENTREPRENEURIAL MODEL WILL INCREASE THE NUMBER OF THERAPIES DISCOVERED AND ENABLE THOSE THERAPIES TO BE AVAILABLE TO DOCTORS AND PATIENTS MORE QUICKLY. ABC2 PROVIDES RESEARCHERS WITH THE PIVOTAL SUPPORT THEY NEED TO MAKE CRITICAL BREAKTHROUGHS. IT FUNDS TRANSLATIONAL RESEARCH AIMED AT FINDING THE FASTEST POSSIBLE ROUTE TO A CURE. ABC2 SUPPORTS A RANGE OF MEDICAL RESEARCH ORGANIZATIONS. 1265113 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 0 0 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 25 0 1 7 1 0 0 0 0 0 0 0 0 0 0 X 9 9 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 0 0 CA X THE ORGANIZATION 2024193140 1717 RHODE ISLAND AVENUE NW NO 700 WASHINGTON DC 20036 STACEY CASE CO-FOUNDER 1.00 X 0 0 0 STEVE CASE CHAIRMAN & CO-FOUNDER 1.00 X 0 0 0 NANCY PFUND MEMBER 1.00 X 0 0 0 DAVID COLE MEMBER 1.00 X 0 0 0 JEAN CASE CO-FOUNDER 1.00 X 0 0 0 DOUG HOLLADAY MEMBER 1.00 X 0 0 0 LARRY PROBST MEMBER 1.00 X 0 0 0 JONATHAN WEINBERG MEMBER 1.00 X 0 0 0 GARY WIMMER MEMBER 1.00 X 0 0 0 DAVID SANDAK VP,SECRETARY/TREASURER 40.00 X 160428 0 39002 MAX WALLACE PRESIDENT AND CEO 40.00 X 326560 0 14305 486988 0 53307 2 0 1 0 0 1303893 657129 1961022 1732 1732 270770 260174 10596 10596 10596 352878 1303893 352878 0 1973350 0 0 12328 911118 911118 540295 115359 147518 277418 288740 60123 78825 149792 5443 2005 1169 2269 11951 2812 3441 5698 43557 7133 11094 25330 51474 51474 176705 59998 30991 85716 16749 5297 2419 9033 6959 6219 740 16669 3600 9469 3600 58772 41389 531 16852 35000 35000 3796 3796 20294 14460 5834 LICENSE AND REGISTRATIO 19930 2451 17479 MEALS AND ENTERTAINMENT 10046 6819 229 2998 WEBSITE & AV 8325 8325 PRINTING 7124 1367 5757 3219 911 2308 2236166 1265113 357738 613315 2696483 2966834 695347 275637 27087 104975 40438 31569 9205 8869 110252 15 17 3538389 3356332 54046 72153 380835 380835 0 62652 434881 515640 X 2365040 2565055 738468 275637 3103508 2840692 3538389 3356332 -262816 0 X X 0 1 X 1 0 X 1874906 3168066 2154714 2575366 1961022 11734074 1874906 3168066 2154714 2575366 1961022 11734074 1143454 10590620 208 215 649 2017 1732 4821 22134 22134 11761029 0.90050 0.89650 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 40438 31569 8869 8869 DUE TO RELATED PARTY 62652 62652 X 2430079 94705 362024 456729 1973350 0 1973350 2692895 94705 362024 456729 2236166 0 2236166 PART X, LINE 2: ABC2 BELIEVES THAT IT HAS APPROPRIATE SUPPORT FOR ANY TAX POSITIONS TAKEN, AND AS SUCH, DOES NOT HAVE ANY UNCERTAIN TAX POSITIONS THAT ARE MATERIAL TO THE FINANCIAL STATEMENTS OR THAT WOULD HAVE AN EFFECT ON ITS TAX-EXEMPT STATUS. THERE ARE NO UNRECOGNIZED TAX BENEFITS OR LIABILITIES THAT NEED TO BE RECORDED. PART XI, LINE 2D - OTHER ADJUSTMENTS: DIRECT FUNDRAISING EXPENSES 362,024. PART XII, LINE 2D - OTHER ADJUSTMENTS: DIRECT FUNDRAISING EXPENSES 362,024. RACE FOR HOPE FUNDRAISING EVENT-DC 1114820 949481 165339 165339 CITY EVENTS 161315 161315 0 4 380636 193097 187539 187539 1656771 1303893 352878 352878 352878 0 1 FLORIDA CENTER FOR BRAIN TUMOR RESEARCH - UNIVERSITY OF FLORIDA HEALTH BOX 100265 UNIVERSITY OF FLORIDA GAINESVILLE FL 32610 591943502 501(C)(3) 100000 TO SUPPORT FCBTR'S 2015/2016 GRANTEES SYAPSE INC 101 UNIVERSITY AVENUE SUITE 230 PALO ALTO CA 94301 263457459 100000 TO USE SYAPSE'S SOFTWARE TO INTERPRET RAW GENOMIC DATA FOR BRAIN CANCER CLINICAL RESEARCH PURPOSES UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE LA JOLLA CA 92093 952544535 501(C)(3) 150000 TO SUPPORT PROPOSAL OF MICRORND AS A BIOMARKER PLATFORM FOR GLIOBLASTOMA TESTING BROAD INSTITUTE 415 MAIN STREET CAMBRIDGE MA 02142 263428781 501(C)(3) 143118 DFCI-10 GBM CASES FOR CLIA SOMATIC WES DANA-FARBER CANCER INST 450 BROOKLINE AVENUE BOSTON MA 02215 042263040 501(C)(3) 300000 TO SUPPORT THE ADAPTIVE CLINICAL TRIAL EFFORT FOR NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS UCLA NEURO-ONCOLOGY PROGRAM 710 WESTWOOD PLAZA LOS ANGELES CA 90095 956006143 501(C)(3) 118000 TO SUPPORT THE INVESTIGATION OF THE USE OF ISOTRETINOIN TO TREAT IDH1 MUTANT GLIOMA PATIENTS 5 1 PART I, LINE 2: ABC2 CLOSELY MONITORS THE PROGRESS OF THE RESEARCHERS IT FUNDS THROUGH ITS GRANT PROGRAM. THE ORGANIZATION REQUIRES SCIENTIFIC PROGRESS REPORTS AND COMPLETE FINANCIAL ACCOUNTING OF EXPENDITURES BEFORE RELEASING ADDITIONAL FUNDS AS WELL AS FINAL GRANT REPORTS INCLUDING FINANCIAL REPORTS. IN ADDITION, ABC2 HOLDS AN ANNUAL SCIENTIFIC MEETING AT WHICH TIME CERTAIN GRANTEES PRESENT THEIR PROGRESS. X X 0 0 0 0 0 0 0 0 0 DAVID SANDAK VP,SECRETARY/TREASURER 160428 0 0 0 0 0 10600 0 28402 0 199430 0 0 0 MAX WALLACE PRESIDENT AND CEO 326560 0 0 0 0 0 0 0 14305 0 340865 0 0 0 X 2 149921 FAIR MARKET VALUE 0 0 0 FORM 990, PART VI, SECTION A, LINE 2 STEPHEN CASE, CHAIRMAN & BOARD MEMBER AND JEAN CASE, BOARD MEMBER ARE CO-FOUNDERS AND SPOUSES. STACEY CASE, BOARD MEMBER AND CO-FOUNDER, IS THE SISTER-IN-LAW OF STEPHEN CASE. THESE BOARD MEMBERS ALSO HAVE BUSINESS RELATIONSHIPS. FORM 990, PART VI, SECTION B, LINE 11B MAX WALLACE, THE CHIEF EXECUTIVE OFFICER OF ACCELERATE BRAIN CANCER CURE, INC. REVIEWS AND SIGNS THE 990. THE 990 IS ALSO REVIEWED BY THE FINANCE COMMITTEE BEFORE IT IS FILED. FORM 990, PART VI, SECTION B, LINE 12C THE BOARD OF DIRECTORS REVIEWS THE CONFLICT OF INTEREST POLICY AT ITS ANNUAL BOARD MEETING. INDEPENDENCE IS ALSO CONFIRMED PRIOR TO THE AWARDING OF ANY EXPENDITURE RESPONSIBILITY GRANT. FORM 990, PART VI, SECTION B, LINE 15A THE CHIEF EXECUTIVE OFFICER JOINED THE ORGANIZATION IN 2008. AS PART OF THE EXECUTIVE SEARCH PROCESS AN INDEPENDENT SEARCH FIRM PERFORMED AN INDUSTRY COMPENSATION ANALYSIS. THE LAST COMPENSATION REVIEW TOOK PLACE ON DECEMBER 2015. THE ORGANIZATION HAD NO KEY EMPLOYEES. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANICAL STATEMENTS AVAILABLE FOR PUBLIC INSPECTION UPON REQUEST. FORM 990, PART XII, LINE 2C THIS PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR.